2023-05-23 08:45:00
In August, Dicot is expected to take its biggest step as a development company with the planned initiation of a phase I clinical trial for the drug candidate LIB-01. Over the past quarter, the company has worked hard to strengthen both its team and finances in preparation for the study start. BioStock reached out to CEO Elin Trampe for her thoughts on the past quarter.
Read the full article at biostock.se (https://www.biostock.se/en/):
https://www.biostock.se/en/2023/05/dicot-heading-towards-summer-with-strengthened-team-and-finances/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se